Atreca: Surges after FDA approves cancer treatment for human trials

Atreca

03/12/2019 17:16

** Drug developer's shares  BCEL.O  jump 24% to $12.5; mark
their best day ever 
    ** U.S. FDA approves BCEL's application to begin study in
humans for its investigational drug, ATRC-101, to treat cancer 
    ** Company expects to begin early-stage study in early 2020
 urn:newsml:reuters.com:*:nGNX8bcpbS
    **  Stock has fallen ~26% from IPO price of $17 in June  

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 0647;))